HomeAI · summaries
Storia in 2 fonti
Ipsen’s Botox rival Dysport charts new horizons with dual phase 3 wins in migraine
In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for the prevention of both episodic and chronic migraines. | In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for the prevention of both episodic and chronic migraines.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront
Ipsen's Dysport meets Phase 3 endpoints in migraine, Tarsus acquires iRenix for $75M+, Alchemab raises $34M, and more.
- ·
fiercepharma.com
Ipsen’s Botox rival Dysport charts new horizons with dual phase 3 wins in migraine
In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for the prevention of both episodic and chronic migraines.…